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Embryonic stem cell research has long been controversial. Although it
opens doors for new medical therapies for several diseases, opponents
claim that it is wrong for ethical reasons. Many western countries are
struggling with the dilemma between fostering biotechnological
innovation in health care by means of patenting and respecting the
core ethical and legal principles of human dignity and integrity. This
clash between ‘new’ and ‘old’ values was ultimately resolved by the
Court of Justice of the European Union in a highly contested ruling in
2011, the Brüstle case.1
Established in the first place to protect the European internal
market – thus economic interests – this ruling, quite paradoxically,
prohibited patents on stem cells from human embryos, as under-
mining human dignity. Although the alternative technology of induced
pluripotent stem cells made the ruling appear already outdated, Brüstle
made some researchers in Europe threaten to migrate to countries
with a more liberal climate towards the patentability of embryonic
stem cells. It seems, however, that the top lawyers in Luxembourg have
been listening to medical scientists, as they did consider allowing
certain methods of producing embryonic stem cell lines.
In its latest ruling, International Stem Cell Corporation v Comp-
troller General of Patents,2 the Court partially lifted its former ban on
the patentability of the so-called parthenogenetic stem cell technique.
In this technique, unfertilised eggs are chemically and electrically
activated to initiate the process of cell division and development
(parthenogenesis). Although the Court confirmed the general princi-
ple that the human body, or a human embryo at any stage, in its
development cannot be patented, simultaneously it ruled that
processes which lead to organisms incapable of developing into
human beings, should be patentable under EU law. Among patent
lawyers, this is considered a major breakthrough in which the Court
seems to recognise that the Brüstle approach, by banning all property
rights on embryonic stem cell techniques, is blocking innovation;
therefore, it qualified as a legal error.
In line with the recommendation of the Court’s adviser, Advocate
General Cruz Villalón, the Court concluded that ‘unfertilised human
ovum whose division and further development to a certain stage have
been stimulated by parthenogenesis, does not constitute a ‘human
embryo’ under European Union law’. It was considered that such an
ovum contains only pluripotent, and not totipotent, cells, and is thus
incapable of development into a complete human being. These
so-called ‘parthenotes’ do not inherently have the capacity of further
development, which makes them open for patenting, thus commercia-
lization. By contrast, this does not hold for a parthenote subjected to
genetic manipulation. A human ovum that has this inherent capacity
must be treated as a ‘human embryo’, and is thus unpatentable.
It seems that the Court with the capability test ‘of commencing the
process of development of a human being’, has struck a balance
between biotech research encouraged by patent law and, on the other
hand, safeguarding human dignity and integrity. At the European
level, there is no justification for a centralised exclusion from
patentability when there is no capability of developing into a human
being. However, the European court leaves it open to the national
courts to decide whether or not human parthenotes have the inherent
capability of developing into a human being. A negative answer, that
is, no inherent capability, will be welcomed by the biotech industry to
invest in parthenote-derived embryonic stem cell techniques and
developing cell-based therapy for clinical applications (eg, regenerative
medicine).3,4 Nevertheless, it remains to be seen whether the ‘inherent
capability test’ is future proof; in other words, does the caveat on
genetic manipulation go far enough? Moreover, we may ask: What’s in
it for patients? Will they benefit from these new medical technologies?
It may seem obvious, but it is important to remember that patented
innovations may harm patients’ access to essential medicines and
medical devices.
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